Delivering Antibody Humanization since 2012.

Over 250 successful projects

Fusion Scientists working in-silico

Our track record speaks for itself. We will humanize your molecule retaining function and maintaining 2-fold affinity, regardless of your parental species.

CDRx™: Diversity is key

For the success of a therapeutic antibody, diversity is key. It’s built into our approach.

We developed our CDRx™ platform after witnessing many failed projects that didn’t consider the value of the ideal biophysical properties utilized by natural evolution. We saw many companies struggle with humanization because the humanized monoclonal antibody construct was limited to a set of human germline sequences.

We offer a unique, proprietary, in silico platform using a database of mature human frameworks, we will deliver a safe and effective humanized variant with a two-fold affinity guarantee.

By utilising a greater diversity of framework sequences, we increase the chances of successfully maintaining the binding function in the humanized format and also the chances of developing stable and robust antibodies that express well downstream.  By creating a diverse pool of mature human frameworks we often improve the affinity or even specificity of the parental antibody.

By triaging frameworks for removal of those with sequence liabilities (incl. predicted T cell epitopes), we ensure that framework sequences are the best possible carriers for your CDRs.

Fusion Antibodies CDRX Humanization Platform

Humanization with Fusion Antibodies:

  • T-cell epitopes using the same prediction tools as the FDA
  • Sequence liabilities for (but not limited to):
  • Deamidation
  • Glycosylation
  • Oxidation
  • Cleavage

These issues can impact expression and purification and generally cause problems downstream. By avoiding these liabilities, you will have a biophysically superior, well-defined single product.

Additional Reading

Multi-specific Figure

Bispecifics – Expanding the potential of immunotherapies

With a quality by design approach, we employ our in silico and protein engineering expertise to design and optimize an engineering program ideal for an antibody candidate, shaped with the endpoint in mind.

Stepping outside of the CDR to create naturalised libraries and humanized antibodies

With their high specificity, efficacy and safety profiles, it’s no wonder that antibodies have become the biggest selling drugs in recent years.
Antibody Fragment Image

Humanized antibody innovation: Top tips for outsourcing

Dr Richard Buick, CTO of Fusion Antibodies explains what he believes to be the top criteria to consider when selecting a humanization outsourcing partner

Contact us about Antibody Humanization